The Plant-derived Hallucinogen, Salvinorin A, Produces Kappa-opioid Agonist-like Discriminative Effects in Rhesus Monkeys
Overview
Affiliations
Rationale: Salvinorin A is the active component of the hallucinogenic plant Salvia divinorum. The potential mode of action of this hallucinogen was unknown until recently. A recent in vitro study detected high affinity and efficacy of salvinorin A at kappa-opioid receptors. It was postulated that salvinorin A would produce discriminative stimulus effects similar to those of a high efficacy kappa-agonist (U69,593) in rhesus monkeys.
Methods: Monkeys were previously trained to discriminate U69,593 (0.0056 or 0.013 mg/kg; s.c.) from vehicle in a food-reinforced FR20 (fixed ratio 20) operant conditioning procedure (n=3). The ability of salvinorin A to cause generalization (> or =90% U69,593-appropriate responding) was examined in time course and cumulative dose-effect curve studies.
Results: All subjects dose-dependently emitted full U69,593-appropriate responding after salvinorin A (0.001-0.032 mg/kg, SC). Salvinorin A-induced generalization started 5-15 min after injection, and dissipated by 120 min. The opioid antagonist quadazocine (0.32 mg/kg) fully blocked the effects of salvinorin A. The kappa-selective antagonist GNTI (1 mg/kg; 24 h pretreatment) did not cause significant antagonism of the effects of salvinorin A (GNTI, under these conditions, was only effective as an antagonist in two of three monkeys). The NMDA antagonist ketamine (0.1-3.2 mg/kg) was not generalized by any subject, indicating that not all compounds that produce hallucinogenic or psychotomimetic effects in humans are generalized by subjects trained to discriminate U69,593.
Conclusions: The naturally occurring hallucinogen salvinorin A produces discriminative stimulus effects similar to those of a high efficacy kappa-agonist in non-human primates.
Pharmacokinetics and Pharmacodynamics of Salvinorin A and : Clinical and Forensic Aspects.
Machado Brito-da-Costa A, Dias-da-Silva D, Gomes N, Dinis-Oliveira R, Madureira-Carvalho A Pharmaceuticals (Basel). 2021; 14(2).
PMID: 33546518 PMC: 7913753. DOI: 10.3390/ph14020116.
Clinical applications of hallucinogens: A review.
Garcia-Romeu A, Kersgaard B, Addy P Exp Clin Psychopharmacol. 2016; 24(4):229-68.
PMID: 27454674 PMC: 5001686. DOI: 10.1037/pha0000084.
Butelman E, Kreek M Front Pharmacol. 2015; 6:190.
PMID: 26441647 PMC: 4561799. DOI: 10.3389/fphar.2015.00190.
Salvinorin A analogs and other κ-opioid receptor compounds as treatments for cocaine abuse.
Kivell B, Ewald A, Prisinzano T Adv Pharmacol. 2014; 69:481-511.
PMID: 24484985 PMC: 4128345. DOI: 10.1016/B978-0-12-420118-7.00012-3.
LC-MS/MS quantification of salvinorin A from biological fluids.
Caspers M, Williams T, Lovell K, Lozama A, Butelman E, Kreek M Anal Methods. 2014; 5(24).
PMID: 24416081 PMC: 3885280. DOI: 10.1039/C3AY40810H.